

14, 15. Please add claims 27-35.

Copies of the claims as amended in (i) amendatory and (ii) plain text form are attached.

REMARKS

Claims 11, 14-15, and 27-35 are in the application. Consideration and substantive examination are respectfully requested.

1. A Requirement for Restriction Under 35 U.S.C. §121, and the Applicants' Response Thereto in The Predecessor Patent Application

A Requirement for Restriction Under 35 U.S.C. §121 was made in the predecessor application serial No.: 09/611,220 between the following inventions:

I. Claims 1-6, drawn to a computerized method of identifying a statistically significant group of datums, classified in at least class 702, subclass 19 and class 706, subclass 15.

II. Claims 7-8, drawn to a method of identifying clinically relevant alleles, classified in at least class 702, subclass 21 and class 706, subclass 15.

III. Claims 9 and 14-15, drawn to a method for predicting an adverse reaction, classified in at least class 702, subclass 19 and class 706, subclass 15.

IV. Claims 10 and 14-15, drawn to a method for predicting optimal drug dosage, classified in at least class 702, subclass 19 and class 706, subclass 15.

V. Claims 11 and 14-15, drawn to methods of identifying suitable therapy, classified in at least class 702, subclass 19 and class 706, subclass 15.

VI. Claims 12 and 14-15, drawn to methods of identifying and predicting susceptibility to disease, classified in at least class 702, subclass 19 and class 706. subclass 15.

VII. Claims 13 and 14-15, drawn to methods of predicting at

100-44202-01

least one clinical result, classified at least class 702, subclass 19 and class 706, subclass 15.

VIII. Claims 16-18, drawn to methods of training a neural net, classified in at least class 702, subclass 19 and class 706, subclass 15.

IX. Claims 19-20, drawn to methods of reducing computational cost and complexity, classified in at least class 702, subclass 19 and class 706, subclass 15.

X. Claim 21, drawn to a method of predicting drug interactions, classified at least class 702, subclass 19 and class 706, subclass 15.

XI. Claims 22-26, drawn to methods of identifying a set of universal functional categories of genomic information, classified at least class 702, subclass 19 and class 706, subclass 15.

Of these inventions, Applicants elected **without** traverse the Invention of Group IV, claims 10 and 14-15. There is **no** change of inventorship.

2. Claims of the Present Divisional Patent Application

In the present divisional patent application Applicants now seek examination of the invention of Group 5, claims 11 and 14-15.

Applicants understand that claims 14-15 will be examined only to the degree that they reflect the elected method of claim 11.

Furthermore, Applicants have added claims 27-35. Applicants maintain that of these added claims, claims 27-28 and 29 are drawn to methods of identifying suitable therapy, classified in at least class 702, subclass 19 and class 706, subclass 15, and are thus suitably grouped, and examined, with claims 10 and 14-15.

Furthermore, claims 30-35 are directed to a neural network performing the method and/or on which the method is performed,

and are thus suitably examined with the other claims.

3. Summary

In consideration of the preceding amendment and accompanying remarks, the present divisional patent application is deemed in condition for substantive examination. The timely action of the Examiner to that end is earnestly solicited.

Applicant's undersigned attorney is at the Examiner's disposal should the Examiner wish to discuss any matter which might expedite prosecution of this case.

Sincerely yours,

William C. Fuess

William C. Fuess
Registration Number 30,054

William C. Fuess
FUESS & DAVIDENAS
Attorneys at Law
10951 Sorrento Valley Road
Suite II-G
San Diego, California 92121-1613
Telephone: (858) 452-8293
Facsimile: (858) 452-6035
E-mail: fuess@pacbell.net

[X] Attorney of Record
[] Filed Under 37 CFR §1.34(a)

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that these documents and the associated divisional patent application are being deposited with the United States Postal Service in an envelope as "Express Mail Post Office to Addressee" mailing Label Number ET655458786US addressed to the: Commissioner of Patents and Trademarks, Washington, D.C. 20231, ATTN: Box Patent Application on the date written below.

February 11, 2002
Date

William C. Fuess
Typed Name of Person
Mailing Correspondence

William C. Fuess
Signature of Person Mailing
Correspondence